Skip to main content
Top
Published in: Diabetologia 7/2010

01-07-2010

In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope

Authors: S. Ueberberg, D. Ziegler, W. Schechinger, J. W. Dietrich, S. Akinturk, H. H. Klein, S. Schneider

Published in: Diabetologia | Issue 7/2010

Login to get access

Abstract

Aims/hypothesis

The aim of the present study was to evaluate in vitro phage display in a beta cell line as a novel strategy for the isolation of beta cell-specific agents/biomarkers.

Methods

A single-chain antibody (SCA) library was pre-incubated with AR42J cells in order to eliminate SCAs with exocrine binding properties. It was then panned against INS-1 cells to select beta cell-targeted antibodies.

Results

By these means, we isolated a novel antibody, SCA B5, that binds rapidly (6.0 min) and with a 450-fold higher specificity to beta cells relative to exocrine cells. We estimated for SCA B5 a binding affinity in the low μmol/l range and 858 binding sites per beta cell. Confocal microscopy showed binding to the beta cell surface and confirmed subsequent internalisation. Moreover, staining of rat and human pancreatic tissue sections with SCA B5 suggests that the target epitope is presented in pancreatic beta cells of different origins. Infrared imaging revealed that labelling of beta cells with tracer SCA B5 is strictly dependent on beta cell mass. With competition assays we excluded insulin, glutamate decarboxylase, C-peptide and islet amyloid polypeptide as SCA B5 targets. In accordance with these predictions, SCA B5 homed in vivo highly selectively to normal beta cells and dysfunctional beta cells of diabetic rats. Moreover, accumulation of radioactively labelled SCA B5 in the pancreas was reduced by 80% after pre-injection with unlabelled SCA B5, thereby confirming the specific uptake in the pancreas.

Conclusions/interpretation

We report a simple strategy for the generation of an SCA targeting a novel beta cell-specific epitope.
Literature
1.
go back to reference Weir GC, Bonner-Weier S, Leahy JL (1990) Islet mass and function in diabetes and transplantation. Diabetes 39:401–405CrossRefPubMed Weir GC, Bonner-Weier S, Leahy JL (1990) Islet mass and function in diabetes and transplantation. Diabetes 39:401–405CrossRefPubMed
2.
go back to reference Butler AE, Janson J, Bonner-Weier S et al (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed Butler AE, Janson J, Bonner-Weier S et al (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed
3.
go back to reference Schneider S (2008) Efforts to develop methods for in vivo evaluation of the native β-cell mass. Diabetes Obes Metab 10(Suppl 4):109–118CrossRefPubMed Schneider S (2008) Efforts to develop methods for in vivo evaluation of the native β-cell mass. Diabetes Obes Metab 10(Suppl 4):109–118CrossRefPubMed
4.
go back to reference Schneider S, Feilen PJ, Schreckenberger M et al (2005) In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 113:388–395CrossRefPubMed Schneider S, Feilen PJ, Schreckenberger M et al (2005) In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 113:388–395CrossRefPubMed
5.
go back to reference Schneider S, Ueberberg S, Korobeynikov A et al (2007) Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept 139:122–127CrossRefPubMed Schneider S, Ueberberg S, Korobeynikov A et al (2007) Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept 139:122–127CrossRefPubMed
6.
go back to reference Wängler B, Schneider S, Thews O et al (2004) Synthesis and evaluation of [18F]repaglinide: a promising radioligand for quantification of pancreatic β-cell mass with positron emission tomography (PET). Nucl Med Biol 31:639–647CrossRefPubMed Wängler B, Schneider S, Thews O et al (2004) Synthesis and evaluation of [18F]repaglinide: a promising radioligand for quantification of pancreatic β-cell mass with positron emission tomography (PET). Nucl Med Biol 31:639–647CrossRefPubMed
7.
go back to reference Sweet IR, Cook DL, Lernmark A et al (2004) Systematic screening of potential beta cell imaging agents. Biochem Biophys Res Commun 314:976–983CrossRefPubMed Sweet IR, Cook DL, Lernmark A et al (2004) Systematic screening of potential beta cell imaging agents. Biochem Biophys Res Commun 314:976–983CrossRefPubMed
8.
go back to reference Hampe CS, Wallen AR, Schlosser M, Ziegler M, Sweet IR (2005) Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic β-cell mass. Exp Clin Endocrinol Diabetes 113:381–387CrossRefPubMed Hampe CS, Wallen AR, Schlosser M, Ziegler M, Sweet IR (2005) Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic β-cell mass. Exp Clin Endocrinol Diabetes 113:381–387CrossRefPubMed
9.
go back to reference Gotthardt M, Lalyko G, van Eerd-Vismale J et al (2004) A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 137:162–167CrossRef Gotthardt M, Lalyko G, van Eerd-Vismale J et al (2004) A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 137:162–167CrossRef
10.
go back to reference Souza F, Simpson N, Raffo A et al (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506–1513CrossRefPubMed Souza F, Simpson N, Raffo A et al (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506–1513CrossRefPubMed
11.
go back to reference Moore A, Bonner-Weir S, Weissleder R (2001) Noninvasive in vivo measurement of beta cell mass in mouse model of diabetes. Diabetes 50:2231–2236CrossRefPubMed Moore A, Bonner-Weir S, Weissleder R (2001) Noninvasive in vivo measurement of beta cell mass in mouse model of diabetes. Diabetes 50:2231–2236CrossRefPubMed
13.
go back to reference Souza F, Freeby M, Hultman K et al (2006) Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem 13:2761–2773CrossRefPubMed Souza F, Freeby M, Hultman K et al (2006) Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem 13:2761–2773CrossRefPubMed
14.
go back to reference Virostko J, Jansen ED, Powers AC (2006) Current status of imaging pancreatic islets. Curr Diab Rep 6:328–332CrossRefPubMed Virostko J, Jansen ED, Powers AC (2006) Current status of imaging pancreatic islets. Curr Diab Rep 6:328–332CrossRefPubMed
15.
go back to reference Ueberberg S, Schneider S (2010) Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo. Regul Pept 160:1–8CrossRefPubMed Ueberberg S, Schneider S (2010) Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo. Regul Pept 160:1–8CrossRefPubMed
16.
go back to reference Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10:625–632CrossRefPubMed Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10:625–632CrossRefPubMed
17.
go back to reference Arap W, Kolonin MG, Trepel M et al (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8:121–127CrossRefPubMed Arap W, Kolonin MG, Trepel M et al (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8:121–127CrossRefPubMed
18.
go back to reference Ueberberg S, Meier JJ, Waengler C et al (2009) Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes 58:2324–34CrossRefPubMed Ueberberg S, Meier JJ, Waengler C et al (2009) Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes 58:2324–34CrossRefPubMed
19.
go back to reference Pasqualini R, Arap W, Rajotte D, Ruoslathi E (2000) In vivo selection of phage display libraries. In: Barbas C, Burton D, Silverma G, Scott J (eds) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press, New York, pp 22.1–22.24 Pasqualini R, Arap W, Rajotte D, Ruoslathi E (2000) In vivo selection of phage display libraries. In: Barbas C, Burton D, Silverma G, Scott J (eds) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press, New York, pp 22.1–22.24
20.
go back to reference Giordano RJ, Marina CV, Lahdenranta J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249–1253CrossRefPubMed Giordano RJ, Marina CV, Lahdenranta J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249–1253CrossRefPubMed
21.
go back to reference Samli KN, McGuire MJ, Newgard CB, Johnston SA, Brown KC (2005) Peptide-mediated targeting of the islets of Langerhans. Diabetes 54:2103–2108CrossRefPubMed Samli KN, McGuire MJ, Newgard CB, Johnston SA, Brown KC (2005) Peptide-mediated targeting of the islets of Langerhans. Diabetes 54:2103–2108CrossRefPubMed
22.
go back to reference Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:393–403CrossRefPubMed Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:393–403CrossRefPubMed
23.
go back to reference Yao VJ, Yao VJ, Ozawa MG, Trepel M, Arap W, McDonald DM, Pasqualini R (2005) Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 166:625–636PubMed Yao VJ, Yao VJ, Ozawa MG, Trepel M, Arap W, McDonald DM, Pasqualini R (2005) Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 166:625–636PubMed
Metadata
Title
In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope
Authors
S. Ueberberg
D. Ziegler
W. Schechinger
J. W. Dietrich
S. Akinturk
H. H. Klein
S. Schneider
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1725-9

Other articles of this Issue 7/2010

Diabetologia 7/2010 Go to the issue